Evidence map›Paper›PMID 38195752›Full record

ArticleNature medicine2024

Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial.

Shubham Pant, Zev A Wainberg, Colin D Weekes, Muhammad Furqan, Pashtoon M Kasi, Craig E Devoe, Alexis D Leal, Vincent Chung, Olca Basturk, Haley VanWyk and 9 more

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 188 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
188citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

188 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Dendritic Cell-Based Immunotherapy in Patients With Resected Pancreatic Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Trial
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

128 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Shubham PantThe University of Texas MD Anderson Cancer Center, Houston, TX, USA. spant@mdanderson.org.ORCID 0000-0001-9281-480X
Zev A WainbergUniversity of California, Los Angeles, Los Angeles, CA, USA.
Colin D WeekesMassachusetts General Hospital, Boston, MA, USA.
Muhammad FurqanUniversity of Iowa, Iowa City, IA, USA.
Pashtoon M KasiUniversity of Iowa, Iowa City, IA, USA.ORCID 0000-0002-5169-7085
Craig E DevoeNorthwell Health, Lake Success, NY, USA.ORCID 0000-0002-2290-1884
Alexis D LealUniversity of Colorado School of Medicine, Aurora, CO, USA.
Vincent ChungCity of Hope, Duarte, CA, USA.
Olca BasturkMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-2747-1366
Haley VanWykElicio Therapeutics, Boston, MA, USA.
Amy M TavaresElicio Therapeutics, Boston, MA, USA.
Lochana M SeenappaElicio Therapeutics, Boston, MA, USA.
James R PerryElicio Therapeutics, Boston, MA, USA.
Thian KheohElicio Therapeutics, Boston, MA, USA.
Lisa K McNeilElicio Therapeutics, Boston, MA, USA.
Esther WelkowskyElicio Therapeutics, Boston, MA, USA.
Peter C DeMuthElicio Therapeutics, Boston, MA, USA.
Christopher M HaqqElicio Therapeutics, Boston, MA, USA. chris.haqq@elicio.com.ORCID 0000-0001-8600-9548
Eileen M O'ReillyMemorial Sloan Kettering Cancer Center, New York, NY, USA. oreillye@mskcc.org.ORCID 0000-0002-8076-9199

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Christopher K Laubenthal · 2000 to 2026
$70.0M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA086862
6 · The paper itself

Abstract

Pancreatic and colorectal cancers are often KRAS mutated and are incurable when tumor DNA or protein persists or recurs after curative intent therapy. Cancer vaccine ELI-002 2P enhances lymph node delivery and immune response using amphiphile (Amph) modification of G12D and G12R mutant KRAS (mKRAS) peptides (Amph-Peptides-2P) together with CpG oligonucleotide adjuvant (Amph-CpG-7909). We treated 25 patients (20 pancreatic and five colorectal) who were positive for minimal residual mKRAS disease (ctDNA and/or serum tumor antigen) after locoregional treatment in a phase 1 study of fixed-dose Amph-Peptides-2P and ascending-dose Amph-CpG-7909; study enrollment is complete with patient follow-up ongoing. Primary endpoints included safety and recommended phase 2 dose (RP2D). The secondary endpoint was tumor biomarker response (longitudinal ctDNA or tumor antigen), with exploratory endpoints including immunogenicity and relapse-free survival (RFS). No dose-limiting toxicities were observed, and the RP2D was 10.0 mg of Amph-CpG-7909. Direct ex vivo mKRAS-specific T cell responses were observed in 21 of 25 patients (84%; 59% both CD4

Indexed as

Colorectal NeoplasmsVaccinesAntigens, NeoplasmBiomarkers, TumorHumansNeoplasm Recurrence, LocalPeptidesProto-Oncogene Proteins p21(ras)Antigens, NeoplasmBiomarkers, TumorPeptidesProto-Oncogene Proteins p21(ras)Vaccines

Identifiers

PMID38195752
PMCPMC10878978

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.